Prescription Pricing Search Engine Waltz Health Enters the Medicare Market
One of the nation’s largest not for profit Medicare Advantage plans, SCAN Health Plan, is the first to use the feature.
digital health © iconimage - stock.adobe.com
Waltz Health is a digital healthcare company that uses an AI-based search engine called Marketplace Search to price, distribute and prescribe medications at the lowest possible cost for patients.
Last week, the company announced that it will soon start offering these services to Medicare beneficiaries by using a customized version of Marketplace Search. Medication adherence information will also be available to members.
The first payer to utilize this feature is SCAN Health Plan, which is one of the largest nonprofit Medicare Advantage health plans in the nation.
"Our tailored versions of Marketplace Search empower the members of Medicare Advantage plans with more choice and information when they're searching for better prices on their prescription drugs, delivering savings for them and helping the plan with member retention," said Waltz Health CEO and cofounder Mark Thierer in a news release. "We're honored to be working with such prestigious Medicare-focused health plan partners and look forward to helping them solve more unique use cases like coverage gaps."
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
More Results for Nerandomilast Reported by BI, This Time for Progressive Pulmonary Fibrosis
February 15th 2025Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.
Read More
